Clinical trial
A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically Suppressed
NCT03299049 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase IIIb, Randomized, Multicenter, Parallel-group, Non-inferiority, Open-label Study Evaluating the Efficacy, Safety, and Tolerability of Long-acting Cabotegravir Plus Long-acting Rilpivirine Administered Every 8 Weeks or Every 4 Weeks in HIV-1-infected Adults Who Are Virologically Suppressed
- Lead sponsor
- ViiV Healthcare
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- October 27, 2017
- Completion date
- December 31, 2029
- Enrollment
- 1,049 (actual)
- Sites
- 118
Conditions
As the registry lists them; a condition with its own page is linked.